Hormones and Cancer

, Volume 1, Issue 4, pp 167–176 | Cite as

Expression of Membrane Progesterone Receptors (mPR/PAQR) in Ovarian Cancer Cells: Implications for Progesterone-Induced Signaling Events

  • Nathan J. Charles
  • Peter Thomas
  • Carol A. Lange
Article

Abstract

The high mortality rates associated with ovarian cancer are largely due to a lack of highly effective treatment options for advanced stage disease; a time when initial diagnosis most commonly occurs. Recent evidence suggests that the steroid hormone, progesterone, may possess anti-tumorigenic properties. With the discovery of a new class of membrane-bound progesterone receptors (mPRs) belonging to the progestin and adipoQ receptor (PAQR) gene family in the ovary, there are undefined mechanisms by which progesterone may inhibit tumor progression. Therefore, our goal was to define potential mPR-dependent signaling mechanisms operative in ovarian cancer cells. We detected abundant mPRα (PAQR7), mPRβ (PAQR8), and mPRγ (PAQR5), but not classical nuclear PR (A or B isoforms) mRNA expression and mPRα protein expression in a panel of commonly used ovarian cancer cell lines. In contrast to mPR action in breast cancer cells, progesterone alone failed to induce changes in cyclic adenosine monophosphate (cAMP) levels in ovarian cancer cells. However, progesterone enhanced cAMP production by β1,2-adrenergic receptors and increased isoproterenol-induced transcription from a cAMP response element (CRE)-driven reporter gene. Independently of β-adrenergic signaling, we additionally observed activation of both JNK1/2 and p38 MAPK in response to progesterone alone. This finding was supported by the results of a screen for potential mPR gene targets. Progesterone induced a significant increase in transcription of the pro-apoptotic marker BAX, whose activity and expression has been linked to JNK1/2 and p38 signaling. Inhibitors of JNK, but not p38, blocked progesterone-induced BAX expression. Taken together, these observations implicate at least two distinct signaling pathways that may be utilized by mPRs in ovarian cancer cells that exhibit regulatory genomic changes. These studies on mPR signaling in ovarian cancer lay the foundation for future work aimed at understanding how progesterone exerts its anti-tumorigenic effects in the ovary and suggest that pharmacologic activation of mPRs, abundantly expressed in ovarian cancers, may provide a new treatment option for patients with advanced stage disease.

Keywords

Ovarian cancer Progesterone Membrane progesterone receptor (mPR) PAQR cAMP Jun kinase (JNK) p38 Mitogen-activated protein kinase Apoptosis 

Notes

Acknowledgements

This work was supported by a grant from the Minnesota Ovarian Cancer Alliance. From the University of Minnesota Masonic Cancer Center, we would like to thank Dr. Douglas Yee, Dr. Amy Skubitz, and Dr. Sundaram Ramakrishnan for providing us with ovarian cancer cell line models and Dr. Paul Mermelstein for the CRE-luciferase reporter construct. We would also like to thank Dr. Patricia Kruk (University of South Florida) for providing us with the 1816-575 cell line.

Conflict of Interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225–249CrossRefPubMedGoogle Scholar
  2. 2.
    Cho KR, Shih Ie M (2009) Ovarian cancer. Annu Rev Pathol 4:287–313CrossRefPubMedGoogle Scholar
  3. 3.
    Leung PC, Choi JH (2007) Endocrine signaling in ovarian surface epithelium and cancer. Hum Reprod Update 13:143–162CrossRefPubMedGoogle Scholar
  4. 4.
    Adami HO, Hsieh CC, Lambe M, Trichopoulos D, Leon D, Persson I et al (1994) Parity, age at first childbirth, and risk of ovarian cancer. Lancet 344:1250–1254CrossRefPubMedGoogle Scholar
  5. 5.
    Thomas HV, Murphy MF, Key TJ, Fentiman IS, Allen DS, Kinlen LJ (1998) Pregnancy and menstrual hormone levels in mothers of twins compared to mothers of singletons. Ann Hum Biol 25:69–75CrossRefPubMedGoogle Scholar
  6. 6.
    Salazar-Martinez E, Lazcano-Ponce EC, Gonzalez Lira-Lira G, Escudero-De los Rios P, Salmeron-Castro J, Hernandez-Avila M (1999) Reproductive factors of ovarian and endometrial cancer risk in a high fertility population in Mexico. Cancer Res 59:3658–3662PubMedGoogle Scholar
  7. 7.
    Tambyraja AL, Sengupta F, MacGregor AB, Bartolo DC, Fearon KC (2004) Patterns and clinical outcomes associated with routine intravenous sodium and fluid administration after colorectal resection. World J Surg 28:1046–1051, discussion 1051–1042CrossRefPubMedGoogle Scholar
  8. 8.
    Modan B, Ron E, Lerner-Geva L, Blumstein T, Menczer J, Rabinovici J et al (1998) Cancer incidence in a cohort of infertile women. Am J Epidemiol 147:1038–1042PubMedGoogle Scholar
  9. 9.
    Syed V, Ulinski G, Mok SC, Yiu GK, Ho SM (2001) Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Res 61:6768–6776PubMedGoogle Scholar
  10. 10.
    Gross TP, Schlesselman JJ, Stadel BV, Yu W, Lee NC (1992) The risk of epithelial ovarian cancer in short-term users of oral contraceptives. Am J Epidemiol 136:46–53PubMedGoogle Scholar
  11. 11.
    Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Lewis JL Jr, Strom BL et al (1994) A case-control study of oral contraceptive use and invasive epithelial ovarian cancer. Am J Epidemiol 139:654–661PubMedGoogle Scholar
  12. 12.
    Ness RB, Grisso JA, Vergona R, Klapper J, Morgan M, Wheeler JE (2001) Oral contraceptives, other methods of contraception, and risk reduction for ovarian cancer. Epidemiology 12:307–312CrossRefPubMedGoogle Scholar
  13. 13.
    Greer JB, Modugno F, Allen GO, Ness RB (2005) Short-term oral contraceptive use and the risk of epithelial ovarian cancer. Am J Epidemiol 162:66–72CrossRefPubMedGoogle Scholar
  14. 14.
    Beral V, Doll R, Hermon C, Peto R, Reeves G (2008) Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23, 257 women with ovarian cancer and 87, 303 controls. Lancet 371:303–314CrossRefPubMedGoogle Scholar
  15. 15.
    Rodriguez GC, Walmer DK, Cline M, Krigman H, Lessey BA, Whitaker RS et al (1998) Effect of progestin on the ovarian epithelium of macaques: cancer prevention through apoptosis? J Soc Gynecol Investig 5:271–276CrossRefPubMedGoogle Scholar
  16. 16.
    Rodriguez GC, Nagarsheth NP, Lee KL, Bentley RC, Walmer DK, Cline M et al (2002) Progestin-induced apoptosis in the Macaque ovarian epithelium: differential regulation of transforming growth factor-beta. J Natl Cancer Inst 94:50–60PubMedGoogle Scholar
  17. 17.
    Lee BH, Hecht JL, Pinkus JL, Pinkus GS (2002) WT1, estrogen receptor, and progesterone receptor as markers for breast or ovarian primary sites in metastatic adenocarcinoma to body fluids. Am J Clin Pathol 117:745–750CrossRefPubMedGoogle Scholar
  18. 18.
    Noguchi T, Kitawaki J, Tamura T, Kim T, Kanno H, Yamamoto T et al (1993) Relationship between aromatase activity and steroid receptor levels in ovarian tumors from postmenopausal women. J Steroid Biochem Mol Biol 44:657–660CrossRefPubMedGoogle Scholar
  19. 19.
    Akahira J, Suzuki T, Ito K, Kaneko C, Darnel AD, Moriya T et al (2002) Differential expression of progesterone receptor isoforms A and B in the normal ovary, and in benign, borderline, and malignant ovarian tumors. Jpn J Cancer Res 93:807–815PubMedGoogle Scholar
  20. 20.
    Lau KM, Mok SC, Ho SM (1999) Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. Proc Natl Acad Sci USA 96:5722–5727CrossRefPubMedGoogle Scholar
  21. 21.
    Thomas P (2008) Characteristics of membrane progestin receptor alpha (mPRalpha) and progesterone membrane receptor component 1 (PGMRC1) and their roles in mediating rapid progestin actions. Front Neuroendocrinol 29:292–312CrossRefPubMedGoogle Scholar
  22. 22.
    Zhu Y, Bond J, Thomas P (2003) Identification, classification, and partial characterization of genes in humans and other vertebrates homologous to a fish membrane progestin receptor. Proc Natl Acad Sci USA 100:2237–2242CrossRefPubMedGoogle Scholar
  23. 23.
    Zhu Y, Rice CD, Pang Y, Pace M, Thomas P (2003) Cloning, expression, and characterization of a membrane progestin receptor and evidence it is an intermediary in meiotic maturation of fish oocytes. Proc Natl Acad Sci USA 100:2231–2236CrossRefPubMedGoogle Scholar
  24. 24.
    Thomas P, Pang Y, Dong J, Groenen P, Kelder J, de Vlieg J et al (2007) Steroid and G protein binding characteristics of the seatrout and human progestin membrane receptor alpha subtypes and their evolutionary origins. Endocrinology 148:705–718CrossRefPubMedGoogle Scholar
  25. 25.
    Karteris E, Zervou S, Pang Y, Dong J, Hillhouse EW, Randeva HS et al (2006) Progesterone signaling in human myometrium through two novel membrane G protein-coupled receptors: potential role in functional progesterone withdrawal at term. Mol Endocrinol 20:1519–1534CrossRefPubMedGoogle Scholar
  26. 26.
    Tubbs C, Thomas P (2009) Progestin signaling through an olfactory G protein and membrane progestin receptor-alpha in Atlantic croaker sperm: potential role in induction of sperm hypermotility. Endocrinology 150:473–484CrossRefPubMedGoogle Scholar
  27. 27.
    Cai Z, Stocco C (2005) Expression and regulation of progestin membrane receptors in the rat corpus luteum. Endocrinology 146:5522–5532CrossRefPubMedGoogle Scholar
  28. 28.
    Ashley RL, Arreguin-Arevalo JA, Nett TM (2009) Binding characteristics of the ovine membrane progesterone receptor alpha and expression of the receptor during the estrous cycle. Reprod Biol Endocrinol 7:42CrossRefPubMedGoogle Scholar
  29. 29.
    Ashley RL, Clay CM, Farmerie TA, Niswender GD, Nett TM (2006) Cloning and characterization of an ovine intracellular seven transmembrane receptor for progesterone that mediates calcium mobilization. Endocrinology 147:4151–4159CrossRefPubMedGoogle Scholar
  30. 30.
    Romero-Sanchez M, Peiper SC, Evans B, Wang Z, Catasus L, Ribe A et al (2008) Expression profile of heptahelical putative membrane progesterone receptors in epithelial ovarian tumors. Hum Pathol 39:1026–1033CrossRefPubMedGoogle Scholar
  31. 31.
    Boulware MI, Weick JP, Becklund BR, Kuo SP, Groth RD, Mermelstein PG (2005) Estradiol activates group I and II metabotropic glutamate receptor signaling, leading to opposing influences on cAMP response element-binding protein. J Neurosci 25:5066–5078CrossRefPubMedGoogle Scholar
  32. 32.
    Pierson-Mullany LK, Lange CA (2004) Phosphorylation of progesterone receptor serine 400 mediates ligand-independent transcriptional activity in response to activation of cyclin-dependent protein kinase 2. Mol Cell Biol 24:10542–10557CrossRefPubMedGoogle Scholar
  33. 33.
    Dressing GE, Thomas P (2007) Identification of membrane progestin receptors in human breast cancer cell lines and biopsies and their potential involvement in breast cancer. Steroids 72:111–116CrossRefPubMedGoogle Scholar
  34. 34.
    Milligan G (2009) G protein-coupled receptor hetero-dimerization: contribution to pharmacology and function. Br J Pharmacol 158:5–14CrossRefPubMedGoogle Scholar
  35. 35.
    Shaw TJ, Keszthelyi EJ, Tonary AM, Cada M, Vanderhyden BC (2002) Cyclic AMP in ovarian cancer cells both inhibits proliferation and increases c-KIT expression. Exp Cell Res 273:95–106CrossRefPubMedGoogle Scholar
  36. 36.
    Mayr B, Montminy M (2001) Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat Rev Mol Cell Biol 2:599–609CrossRefPubMedGoogle Scholar
  37. 37.
    Syed V, Mukherjee K, Lyons-Weiler J, Lau KM, Mashima T, Tsuruo T et al (2005) Identification of ATF-3, caveolin-1, DLC-1, and NM23-H2 as putative antitumorigenic, progesterone-regulated genes for ovarian cancer cells by gene profiling. Oncogene 24:1774–1787CrossRefPubMedGoogle Scholar
  38. 38.
    Matsukawa J, Matsuzawa A, Takeda K, Ichijo H (2004) The ASK1-MAP kinase cascades in mammalian stress response. J Biochem 136:261–265CrossRefPubMedGoogle Scholar
  39. 39.
    Miller WE, Lefkowitz RJ (2001) Expanding roles for beta-arrestins as scaffolds and adapters in GPCR signaling and trafficking. Curr Opin Cell Biol 13:139–145CrossRefPubMedGoogle Scholar
  40. 40.
    Arafat WO, Gomez-Navarro J, Xiang J, Barnes MN, Mahasreshti P, Alvarez RD et al (2000) An adenovirus encoding proapoptotic Bax induces apoptosis and enhances the radiation effect in human ovarian cancer. Mol Ther 1:545–554CrossRefPubMedGoogle Scholar
  41. 41.
    Marone M, Scambia G, Mozzetti S, Ferrandina G, Iacovella S, De Pasqua A et al (1998) bcl-2, bax, bcl-XL, and bcl-XS expression in normal and neoplastic ovarian tissues. Clin Cancer Res 4:517–524PubMedGoogle Scholar
  42. 42.
    Wu GS (2004) The functional interactions between the p53 and MAPK signaling pathways. Cancer Biol Ther 3:156–161PubMedGoogle Scholar
  43. 43.
    Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D et al (1996) Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 56:556–562PubMedGoogle Scholar
  44. 44.
    Fister S, Gunthert AR, Aicher B, Paulini KW, Emons G, Grundker C (2009) GnRH-II antagonists induce apoptosis in human endometrial, ovarian, and breast cancer cells via activation of stress-induced MAPKs p38 and JNK and proapoptotic protein Bax. Cancer Res 69:6473–6481CrossRefPubMedGoogle Scholar
  45. 45.
    Kim BJ, Ryu SW, Song BJ (2006) JNK- and p38 kinase-mediated phosphorylation of Bax leads to its activation and mitochondrial translocation and to apoptosis of human hepatoma HepG2 cells. J Biol Chem 281:21256–21265CrossRefPubMedGoogle Scholar
  46. 46.
    Mansouri A, Ridgway LD, Korapati AL, Zhang Q, Tian L, Wang Y et al (2003) Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J Biol Chem 278:19245–19256CrossRefPubMedGoogle Scholar
  47. 47.
    Lee LF, Li G, Templeton DJ, Ting JP (1998) Paclitaxel (Taxol)-induced gene expression and cell death are both mediated by the activation of c-Jun NH2-terminal kinase (JNK/SAPK). J Biol Chem 273:28253–28260CrossRefPubMedGoogle Scholar
  48. 48.
    Givant-Horwitz V, Davidson B, Lazarovici P, Schaefer E, Nesland JM, Trope CG et al (2003) Mitogen-activated protein kinases (MAPK) as predictors of clinical outcome in serous ovarian carcinoma in effusions. Gynecol Oncol 91:160–172CrossRefPubMedGoogle Scholar
  49. 49.
    Bu SZ, Yin DL, Ren XH, Jiang LZ, Wu ZJ, Gao QR et al (1997) Progesterone induces apoptosis and up-regulation of p53 expression in human ovarian carcinoma cell lines. Cancer 79:1944–1950CrossRefPubMedGoogle Scholar
  50. 50.
    Syed V, Ho SM (2003) Progesterone-induced apoptosis in immortalized normal and malignant human ovarian surface epithelial cells involves enhanced expression of FasL. Oncogene 22:6883–6890CrossRefPubMedGoogle Scholar
  51. 51.
    Syed V, Mukherjee K, Godoy-Tundidor S, Ho SM (2007) Progesterone induces apoptosis in TRAIL-resistant ovarian cancer cells by circumventing c-FLIPL overexpression. J Cell Biochem 102:442–452CrossRefPubMedGoogle Scholar
  52. 52.
    Chao KC, Wang PH, Yen MS, Chang CC, Chi CW (2005) Role of estrogen and progesterone in the survival of ovarian tumors–a study of the human ovarian adenocarcinoma cell line OC-117-VGH. J Chin Med Assoc 68:360–367CrossRefPubMedGoogle Scholar
  53. 53.
    Belinson JL, McClure M, Badger G (1987) Randomized trial of megestrol acetate vs. megestrol acetate/tamoxifen for the management of progressive or recurrent epithelial ovarian carcinoma. Gynecol Oncol 28:151–155CrossRefPubMedGoogle Scholar
  54. 54.
    Chen X, Feng Y (2003) Effect of progesterone combined with chemotherapy on epithelial ovarian cancer. Chin Med J (Engl) 116:388–391Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Nathan J. Charles
    • 1
    • 2
  • Peter Thomas
    • 3
  • Carol A. Lange
    • 1
    • 2
  1. 1.Department of Medicine, Division of Hematology, Oncology, and TransplantationUniversity of Minnesota Masonic Cancer CenterMinneapolisUSA
  2. 2.Department of PharmacologyUniversity of Minnesota Masonic Cancer CenterMinneapolisUSA
  3. 3.University of Texas Marine Science InstitutePort AransasUSA

Personalised recommendations